摘要
应用单克隆抗体和流式细胞仪技术,测定10例正常人和87例急性髓细胞白血病骨髓c-kit受体和CD34的表达,探讨其与化疗疗效的关系。正常人骨髓c-kit受体和CD34表达率分别为0.5％和1.7％。c-kit受体表达率与白血病细胞比例之间无相关性;以大于20％细胞表达为阳性,患者c-kit受体和CD34阳性率分别为52％和37％。c-kit受体和CD34阳性病例缓解率较低,差异有显著性p<0.01。c-kit受体及CD34共同表达者疗效尤差,p<0.005。结论为测定c-kit受体及CD34可做为预测急性髓细胞白血病疗效的因素。
Using monoclonal antibody and flow cytometry, expressions of c-kit receptor and CD34 of bone marrow cells in 10 normal subjects and 87 patients with acute myeloid leukemias have been determined, and correlation between the expressions and chemotherapeutic effect studied. Expressing rate of c-kit and CD34 in normal subjects marrow cells is 0.5 %, 1.7% respectively. There is no correlation between c - kit receptor expressing rate and luekemic cell ratio. According to standard that expression of more than 20 % cells is positive, positive rate of c- kit receptor and CD34 in AMLs is 52 % , 37 % respectively, the rate of complete remission in c-kit receptor and CD34 positive group is lower than that of negative group, the difference is significant, p < 0. 01. There is the worst chemotherapeutic effect in coexpression of c - kit receptor and CD34, p < 0.005. It comes conclusion that determining of the expression of c - kit receptor and CD34 may act as factors for predicting chemotherapeutic effect in acute myeloid leukemia.
